![]() |
JOURNAL TOOLS |
Publishing options |
eTOC |
To subscribe |
Submit an article |
Recommend to your librarian |
ARTICLE TOOLS |
Publication history |
Reprints |
Permissions |
Cite this article as |
Share |


YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
REVIEW
Minerva Respiratory Medicine 2021 December;60(4):136-41
DOI: 10.23736/S2784-8477.21.01921-0
Copyright © 2021 EDIZIONI MINERVA MEDICA
language: English
COVID-19 vaccines: challenges and solutions
Zeinab MOHSENI AFSHAR 1, Arefeh BABAZADEH 2, Alireza JANBAKHSH 1, Mandana AFSHARIAN 1, Soheil EBRAHIMPOUR 2 ✉
1 Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran; 2 Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared a global emergency by the World Health Organization (WHO). Several ways have been used to control and manage the COVID-19 pandemic. Among them, development of vaccines could be an important breakthrough against novel virus. It is important to note that the candidate vaccine is expected to work against infection and transmission. To date, many COVID-19 vaccine clinical trials have been registered worldwide. However, some vaccine candidates could meet adequate standards for effectiveness and safety. In the current review, we discussed the effectiveness, safety, target population, and hesitancy of COVID-19 vaccines.
KEY WORDS: SARS-CoV-2; COVID-19; Vaccines